Low-Dose Naltrexone as a Potential Healthspan-Enhancing Intervention in a Normative Aging Cohort: Changes in Quality of Life and Immune Health Metrics

Опубликована: Авг. 7, 2024

Low-dose naltrexone (LDN) has been suggested to target the multiple hallmarks of aging and improve healthspan metrics in humans.However, date, no studies have evaluated LDNs potential as a gerotherapeutic.We collected real-world data utilizing short form 36 quality life (QoL) assay, immune status questionnaire, patient-reported health assessment evaluate effectiveness LDN for improving normative cohort still within their healthspan.Most participants taking ≥3 months (69.2%) had significant improvement mean QoL scores (29.9%).The largest improvements were observed categories energy fatigue, physical role limitations, emotional social functioning, pain.Participants also exhibited function (24.6%).Data from at ≥4 weeks (N = 5500) ≥10 1450) use revealed that majority reported pain, inflammation, mood.A healthspan-enhancing drug should demonstrate ability enhance individuals before age-related diseases disability arise, thereby extending period spent good health.We found 45% responders average above-average baseline scores, which increased 76.6% after treatment.Furthermore, 23.8% able discontinue other medications 10.5% avoiding planned clinical procedures.These suggest might play enhancing healthspan, warranting further research into its geroprotective effects.

Язык: Английский

Daily consumption of ketone ester, bis octanoyl (R)-1,3-butanediol does not impact functional and quality of life outcomes in healthy older adults, a randomized, parallel arm, double-blind, placebo-controlled study

medRxiv (Cold Spring Harbor Laboratory), Год журнала: 2024, Номер unknown

Опубликована: Сен. 18, 2024

Abstract Background Ketone bodies are metabolites produced during fasting or on a ketogenic diet that have pleiotropic effects the inflammatory and metabolic aging pathways underpinning frailty in vivo models. esters (KEs) compounds induce hyperketonemia without dietary changes may impact physical cognitive function young adults. The functional of KEs not been studied older Objectives Our long-term goal is to examine if modulate biology mechanisms clinical outcomes relevant Here, we report exploratory quality-of-life outcome measures collected 12-week safety tolerability study KE ( NCT05585762 ). Design Randomized, placebo-controlled, double-blinded, parallel-group, pilot trial 12-weeks daily ingestion. Setting Clinical Research Unit at Buck Institute for Aging, California. Participants: Community-dwelling adults (≥ 65 years), independent activities living, with no unstable acute medical conditions (n = 30). Intervention Subjects were randomly allocated (1:1) consume 25 g either (bis-octanoyl (R)-1,3-butanediol) taste, appearance, calorie-matched placebo (PLA) containing canola oil. Measurements Longitudinal change function, quality life assessed as n 23 completers 11 PLA, 12 KE). A composite describe vigor-frailty continuum was calculated. Heart rate activity measured throughout using digital wearables. Results There statistically significant longitudinal differences between groups functional, activity-based outcomes. Conclusion Daily ingestion did affect end points this cohort healthy Future work will address these endpoints primary secondary larger pre-frail

Язык: Английский

Senolytic Vaccines from the Central and Peripheral Tolerance Perspective

Vaccines, Год журнала: 2024, Номер 12(12), С. 1389 - 1389

Опубликована: Дек. 10, 2024

Preventive medicine has proven its long-term effectiveness and economic feasibility. Over the last century, vaccination saved more lives than any other medical technology. At present, preventative measures against most infectious diseases are successfully used worldwide; in addition, platforms oncological even autoimmune being actively developed. same time, development of led to an increase both life expectancy proportion age-associated diseases, which pose a heavy socio-economic burden. In this context, vaccine-based approaches for prevention or treatment age-related opens up broad prospects extending period active longevity high potential. It is well known that associated with accumulation senescent cells various organs tissues. been demonstrated elimination such leads restoration functions, rejuvenation, extension experimental animals. However, vaccines complicated by their antigenic heterogeneity lack unique marker. body’s own cells, may be reason low immunogenicity. This mini-review discusses mechanisms central peripheral tolerance influence formation anti-senescent immune response responsible age.

Язык: Английский